



BioAegis Therapeutics Wins *Best Presentation Award* at the CM-Equity Conference in Munich, Germany

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 22, 2016 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN) won *Best Presentation Award* at the CM-Equity Conference in Munich, Germany. Presenting for the company was Mr. Steven Cordovano, Co-Founder and Vice President of Investor Relations.

CM-Equity is a diversified financial services firm in Munich, Germany with a wide ranging customer base that includes institutional investors, family offices and fund managers.

Plasma Gelsolin

The highly abundant endogenous plasma protein, pGSN, harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection. Decreased plasma gelsolin levels at presentation are found in patients with diverse infectious and non-infectious inflammatory diseases, who are at high risk for developing serious complications.

Based on recent breakthrough findings in studies conducted at the TH Chan Harvard School of Public Health, BioAegis is preparing to conduct Phase 2 studies in severe community acquired pneumonia.

Severe Community Acquired Pneumonia is a leading cause of death in the US and around the world. The adverse outcomes, including organ failure and mortality, generate enormous cost to the health care system. As a result of organ damage, survivors often require ongoing care after being discharged from the ICU due to lingering neurocognitive and functional disabilities. This puts an enormous incremental strain on the health care system. Plasma gelsolin repletion therapy is expected to reduce these adverse outcomes as well as the costs associated with severe disease.

BioAegis Therapeutics was founded by a group of highly experienced pharmaceutical and financial executives. Its mission is to harness the body's innate immune system to address serious outcomes in diseases driven by inflammation.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For further information:

Steven Cordovano, 203-952-6373
Email: scordovano@bioaegistherapeutics.com
www.bioaegistherapeutics.com